Annual report
4543.TEDINET S100R4TX
Period2022-04-01 → 2023-03-31
Filed2023-06-28
StandardIFRS
ConsolidatedYes
Data checks21 of 21 passed
Key figures · 157
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥820.2bn | 2022-04-01 → 2023-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥703.3bn | 2021-04-01 → 2022-03-31 | Cons. | Revenue IFRS |
| Revenue | ¥613.8bn | 2020-04-01 → 2021-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥628.9bn | 2019-04-01 → 2020-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Revenue | ¥599.5bn | 2018-04-01 → 2019-03-31d | Cons. | Revenue IFRS (5-year summary) |
| Operating income | ¥117.3bn | 2022-04-01 → 2023-03-31 | Cons. | Operating profit loss IFRS |
| Operating income | ¥116.0bn | 2021-04-01 → 2022-03-31 | Cons. | Operating profit loss IFRS |
| Profit before tax | ¥116.1bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥114.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss before tax IFRS |
| Profit before tax | ¥97.1bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥106.5bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Profit before tax | ¥102.7bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss before tax IFRS (5-year summary) |
| Net income (owners) | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥88.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent IFRS |
| Net income (owners) | ¥77.3bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥85.2bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income (owners) | ¥79.5bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent IFRS (5-year summary) |
| Net income | ¥89.3bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss IFRS |
| Net income | ¥88.8bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss IFRS |
| Total assets | ¥1.60T | at 2023-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.47T | at 2022-03-31 | Cons. | Assets IFRS |
| Total assets | ¥1.35T | at 2021-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.24T | at 2020-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total assets | ¥1.12T | at 2019-03-31d | Cons. | Total assets IFRS (5-year summary) |
| Total liabilities | ¥491.2bn | at 2023-03-31 | Cons. | Liabilities IFRS |
| Total liabilities | ¥461.4bn | at 2022-03-31 | Cons. | Liabilities IFRS |
| Net assets / equity | ¥1.11T | at 2023-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥1.01T | at 2022-03-31 | Cons. | Equity IFRS |
| Net assets / equity | ¥856.7bn | at 2021-03-31d | Cons. | Equity IFRS |
| Equity (owners) | ¥1.11T | at 2023-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥1.01T | at 2022-03-31 | Cons. | Equity attributable to owners of parent IFRS |
| Equity (owners) | ¥856.7bn | at 2021-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥754.8bn | at 2020-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Equity (owners) | ¥698.0bn | at 2019-03-31d | Cons. | Equity attributable to owners of parent IFRS (5-year summary) |
| Cash & equivalents | ¥187.3bn | at 2023-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥205.3bn | at 2022-03-31 | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥200.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents IFRS |
| Cash & equivalents | ¥166.9bn | at 2020-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Cash & equivalents | ¥123.0bn | at 2019-03-31d | Cons. | Cash and cash equivalents IFRS (5-year summary) |
| Operating cash flow | ¥117.5bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥141.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities IFRS |
| Operating cash flow | ¥121.5bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥117.5bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Operating cash flow | ¥93.6bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in operating activities IFRS (5-year summary) |
| Investing cash flow | −¥59.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥78.5bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investing activities IFRS |
| Investing cash flow | −¥85.3bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥84.7bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Investing cash flow | −¥74.8bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in investing activities IFRS (5-year summary) |
| Financing cash flow | −¥86.6bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥70.9bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities IFRS |
| Financing cash flow | −¥7.4bn | 2020-04-01 → 2021-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | ¥14.0bn | 2019-04-01 → 2020-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| Financing cash flow | −¥67.5bn | 2018-04-01 → 2019-03-31d | Cons. | Cash flows from used in financing activities IFRS (5-year summary) |
| EPS (basic) | ¥119 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥117.45 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share IFRS |
| EPS (basic) | ¥102.33 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥113.96 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (basic) | ¥108.7 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥118.95 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥117.38 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings loss per share IFRS |
| EPS (diluted) | ¥102.11 | 2020-04-01 → 2021-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥112.61 | 2019-04-01 → 2020-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| EPS (diluted) | ¥104.97 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings loss per share IFRS (5-year summary) |
| Net assets per share | ¥1,492.15 | at 2023-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,338.46 | at 2022-03-31 | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,133.13 | at 2021-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥1,003.36 | at 2020-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Net assets per share | ¥939.6 | at 2019-03-31d | Cons. | Equity to asset ratio IFRS (5-year summary) |
| Equity ratio | 69.3% | at 2023-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 68.7% | at 2022-03-31 | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 63.4% | at 2021-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 60.8% | at 2020-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| Equity ratio | 62.3% | at 2019-03-31d | Cons. | Ratio of owners equity to gross assets IFRS (5-year summary) |
| ROE | 8.4% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 9.5% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 9.6% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 11.7% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| ROE | 12.7% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity IFRS (5-year summary) |
| Employees | 30,207 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 28,294 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 26,482 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 26,438 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 25,378 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥375.0bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥341.4bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥316.4bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥319.0bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥307.0bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥67.8bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥59.4bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥91.1bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥79.4bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥65.3bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥80.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥72.9bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥99.7bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥78.8bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥79.0bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥62.8bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥52.0bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥65.3bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥58.1bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥1.33T | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥1.28T | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥1.26T | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.15T | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥1.04T | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥566.1bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥517.3bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥765.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥765.4bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥725.2bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥687.2bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥624.9bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥91.5bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥98.3bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥105.22 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥83.04 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.89 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.31 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥79.47 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥105.17 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥82.99 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥68.74 | 2020-04-01 → 2021-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥86.29 | 2019-04-01 → 2020-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥76.78 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥40 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥34 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥29 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥54 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,027.34 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,011.08 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥958.26 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥912.44 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥840.16 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 57.4% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.6% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 57.4% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 59.9% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 10.3% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.4% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.4% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.2% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 747,682,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 759,521,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 759,521,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 759,521,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 379,760,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 5,457 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 5,377 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 5,247 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 5,087 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 4,908 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 36
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥1.5bn |
| Reconciling Itemsreconciling | revenue external | 2022-04-01 → 2023-03-31 | ¥243m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥142m |
| Blood And Cell Technologies Companyreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥21.5bn |
| Blood And Cell Technologies Companyreportable segment | employees | at 2023-03-31 | 6908 pure |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥147.6bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥11.2bn |
| Cardiac And Vascular Companyreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥31.9bn |
| Cardiac And Vascular Companyreportable segment | employees | at 2023-03-31 | 16060 pure |
| Cardiac And Vascular Companyreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥480.6bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥112.2bn |
| Medical Care Solutions Companyreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥20.9bn |
| Medical Care Solutions Companyreportable segment | employees | at 2023-03-31 | 6201 pure |
| Medical Care Solutions Companyreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥191.7bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥14.8bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥74.3bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥820.0bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥138.2bn |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥4.4bn |
| Reconciling Itemsreconciling | revenue external | 2021-04-01 → 2022-03-31 | ¥251m |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥3.2bn |
| Blood And Cell Technologies Companyreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥17.6bn |
| Blood And Cell Technologies Companyreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥120.6bn |
| Blood And Cell Technologies Companyreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥20.8bn |
| Cardiac And Vascular Companyreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥32.0bn |
| Cardiac And Vascular Companyreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥397.1bn |
| Cardiac And Vascular Companyreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥93.2bn |
| Medical Care Solutions Companyreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥15.3bn |
| Medical Care Solutions Companyreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥185.3bn |
| Medical Care Solutions Companyreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥23.6bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥64.8bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥703.1bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥137.7bn |
| Blood And Cell Technologies Companyreportable segment | employees | at 2023-03-31 | 249 pure |
| Cardiac And Vascular Companyreportable segment | employees | at 2023-03-31 | 1841 pure |
| Medical Care Solutions Companyreportable segment | employees | at 2023-03-31 | 2375 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,773
| Item | Context | Value | Unit |
|---|---|---|---|
| Net increase decrease in cash and cash equivalents IFRS | CurrentYearDuration | -17929000000 | JPY |
| Cash and cash equivalents IFRS | Prior2YearInstant | 200770000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 205251000000 | JPY |
| Cash and cash equivalents IFRS | Prior1YearInstant | 205251000000 | JPY |
| Cash and cash equivalents IFRS | CurrentYearInstant | 187322000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 397130000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 185335000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 120586000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReportableSegmentsMember | 703052000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration_ReconcilingItemsMember | 251000000 | JPY |
| Revenue from external customers IFRS | Prior1YearDuration | 703303000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 93227000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 23604000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 20841000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration_ReportableSegmentsMember | 137673000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration_ReconcilingItemsMember | -3232000000 | JPY |
| Segment profit loss IFRS | Prior1YearDuration | 134441000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | -7451000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | － | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | -8487000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration_ReportableSegmentsMember | -15939000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration_ReconcilingItemsMember | -125000000 | JPY |
| Amortization of intangible assets acquired through business combinations IFRS | Prior1YearDuration | -16064000000 | JPY |
| Non recurring profit or loss IFRS | Prior1YearDuration | -2415000000 | JPY |
| Operating profit loss IFRS | Prior1YearDuration | 115960000000 | JPY |
| Finance income IFRS | Prior1YearDuration | 1062000000 | JPY |
| Finance costs IFRS | Prior1YearDuration | 2961000000 | JPY |
| Share of profit loss of investments accounted for using equity method IFRS | Prior1YearDuration | 440000000 | JPY |
| Profit loss before tax IFRS | Prior1YearDuration | 114501000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 29776000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 14178000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 15613000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_ReportableSegmentsMember | 59568000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration_ReconcilingItemsMember | -686000000 | JPY |
| Depreciation and amortization operating expenses IFRS | Prior1YearDuration | 58882000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 31954000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 15285000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 17599000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration_ReportableSegmentsMember | 64839000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration_ReconcilingItemsMember | 4390000000 | JPY |
| Capital expenditures IFRS | Prior1YearDuration | 69230000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 480610000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 191749000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 147605000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_ReportableSegmentsMember | 819965000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration_ReconcilingItemsMember | 243000000 | JPY |
| Revenue from external customers IFRS | CurrentYearDuration | 820209000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000CardiacAndVascularCompanyReportableSegmentMember | 112155000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000MedicalCareSolutionsCompanyReportableSegmentMember | 14848000000 | JPY |
| Segment profit loss IFRS | CurrentYearDuration_jpcrp030000-asr_E01630-000BloodAndCellTechnologiesCompanyReportableSegmentMember | 11163000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 21 of 21 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |